ID   K25-iPSC
AC   CVCL_DD63
DR   Wikidata; Q54899276
RX   PubMed=27191603;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; HGNC:18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Unspecified (PubMed=27191603).
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
CC   Cell type: Fibroblast of skin; CL=CL_0002620.
ST   Source(s): PubMed=27191603
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 9,12
ST   D16S539: 8,13
ST   D21S11: 29,30
ST   D5S818: 11,12
ST   D7S820: 10,11
ST   TH01: 7,9
ST   TPOX: 8,9
ST   vWA: 17,18
DI   NCIt; C198605; Parkinson disease 8, autosomal dominant
DI   ORDO; Orphanet_411602; Hereditary late-onset Parkinson disease
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_DD50 ! ND29802
SX   Male
AG   52Y
CA   Induced pluripotent stem cell
DT   Created: 13-07-16; Last updated: 19-12-24; Version: 12
//
RX   PubMed=27191603; DOI=10.1371/journal.pone.0154890; PMCID=PMC4871453;
RA   Momcilovic O., Sivapatham R., Oron T.R., Meyer M., Mooney S.,
RA   Rao M.S., Zeng X.-M.;
RT   "Derivation, characterization, and neural differentiation of
RT   integration-free induced pluripotent stem cell lines from Parkinson's
RT   disease patients carrying SNCA, LRRK2, PARK2, and GBA mutations.";
RL   PLoS ONE 11:E0154890-E0154890(2016).
//